Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VEGF Trap Eye · 1 trial · 1 indication
Number of participants with AEs summarized by category
| Arm | Type | Description |
|---|---|---|
| Intravitreal Aflibercept Injection (EYLEA, VEGF Trap-Eye) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| VEGF Trap Eye | DRUG | Intravitreal injection |
Inclusion Criteria: * Prior participation in VEGF Trap-Eye Phase I and II studies Exclusion Criteria: * Any ocular or systemic adverse events that would preclude participation * Presence of any condition that would jeopardize subject's participation
VEGF Trap Eye is an investigational ophthalmology treatment being studied for macular edema, diabetic macular edema, pathologic myopia, macular degeneration, and macular edema secondary to central retinal vein occlusion. It is a small molecule developed by Regeneron Pharmaceuticals for conditions affecting the retina and vision.
VEGF Trap Eye targets vascular endothelial growth factor (VEGF), a protein that promotes abnormal blood vessel growth and leakage in the eye. By binding to VEGF, the drug aims to reduce retinal swelling and neovascularization associated with conditions like diabetic macular edema and macular degeneration.
VEGF Trap Eye is developed by Regeneron Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker REGN. Regeneron is conducting clinical trials to evaluate the drug's safety and efficacy in multiple eye conditions.
VEGF Trap Eye is in Phase 2 clinical development, with one completed Phase 2 trial. Additional Phase 3 trials have also been completed, but the drug remains investigational and is not yet approved by regulatory authorities. It is still undergoing clinical evaluation for its safety and effectiveness.
VEGF Trap Eye has been studied in several completed trials, including NCT00527423 (Phase 2, macular degeneration), NCT01249664 (Phase 3, pathologic myopia), NCT01331681 (Phase 3, diabetic macular edema), and NCT01512966 (Phase 3, macular edema in Japan). These trials enrolled a total of 406 participants.
Yes, VEGF Trap Eye is also known as aflibercept. Clinical trials such as NCT01331681 refer to it as intravitreal aflibercept injection. The drug is being developed by Regeneron Pharmaceuticals for various retinal conditions, including diabetic macular edema and macular degeneration.